Form 4: Pacific Biosciences Director Receives Stock Option Grant

Director Kathy Ordonez was granted 223,492 stock options in Pacific Biosciences of California, Inc. as part of standard compensation.

Summary

• Director Kathy Ordonez received a grant of 223,492 stock options for Pacific Biosciences of California, Inc. (PACB).
• The options have an exercise price of $1.58 per share.
• The grant date is June 3, 2026, with an expiration date of June 3, 2036.
• The options vest monthly over a one-year period, contingent upon continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's operational outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest monthly over one year, provided the director remains in service, aligning the director's tenure with company performance through 2027.

Industry Context

StockSavvy.ai notes that equity grants for board members are standard practice in the biotechnology sector to ensure retention and alignment with long-term strategic goals.

Comparison to Industry Standards

• The use of monthly vesting over one year for director compensation is consistent with standard corporate governance practices for mid-cap biotech firms.
• The exercise price reflects the market value at the time of the grant, adhering to standard SEC and tax compliance requirements.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options beginning July 3, 2026.

Key Dates

Keywords

PACB, Pacific Biosciences, Form 4, Insider Trading, Stock Options, Director Compensation